Biggest News Aggregation in the World
📰 Nasdaq Ctxr News

Nasdaq Ctxr News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Ctxr. Real-time updates on events, politics, business and more.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 17,210,000 shares, a decrease of 7.2% from the September 30th total of 18,540,000 shares. Based on an average daily trading volume, of 997,100 shares, the days-to-cover […]
United States Citius Pharmaceuticals Stock Performance Citius Pharmaceuticals Inc News Ratings For Citius Pharmaceuticals Daily Barclays Plc Allspring Global Investments Holdings

Citius Pharmaceuticals (NASDAQ:CTXR) Price Target Cut to $4.00

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) had its target price decreased by research analysts at HC Wainwright from $6.00 to $4.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 337.59% from the company’s […]
Meitav Investment House Ltd Virtu Financial Citius Pharmaceuticals Institutional Investors Weigh In On Citius Pharmaceuticals Citius Pharmaceuticals Price Performance Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Up 13.4% in May

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 13,760,000 shares, an increase of 13.4% from the May 15th total of 12,130,000 shares. Based on an average daily volume of 1,450,000 shares, the short-interest ratio is […]
Citius Pharmaceuticals Inc Chelsea Counsel Co Citius Pharmaceuticals Price Performance Citius Pharmaceuticals Company Profile Boothbay Fund Management Institutional Investors Weigh In On Citius Pharmaceuticals
Source: wkrb13.com

Rocket Pool ETH (RETH) Self Reported Market Cap Achieves $639.56 Million

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) – Investment analysts at HC Wainwright decreased their Q3 2023 earnings per share estimates for Citius Pharmaceuticals in a report issued on Tuesday, May 30th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($0.07) per share for the quarter, down from their previous estimate […]
News Ratings For Citius Pharmaceuticals Daily Geode Capital Management Northern Trust Corp Millennium Management Vanguard Group Inc Capital Partners

Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 6.7%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 13,600,000 shares, a growth of 6.7% from the April 15th total of 12,750,000 shares. Based on an average trading volume of 953,100 shares, the short-interest ratio is […]
Squarepoint Ops Citius Pharmaceuticals Citius Pharmaceuticals Trading Down Citius Pharmaceuticals Company Profile Hedge Funds Weigh In On Citius Pharmaceuticals News Ratings For Citius Pharmaceuticals Daily

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 12,750,000 shares, an increase of 6.5% from the March 31st total of 11,970,000 shares. Approximately 9.5% of the shares of the company are short […]
Renaissance Technologies Citius Pharmaceuticals Inc Virtu Financial Blair William Co Advisor Group Holdings Inc News Ratings For Citius Pharmaceuticals Daily

Citius Pharmaceuticals (NASDAQ:CTXR) Receives "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $6.00 price target on the stock. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q2 2023 earnings at ($0.05) EPS, Q3 2023 earnings […]
Marshall Wace Citius Pharmaceuticals Price Performance Hedge Funds Weigh In On Citius Pharmaceuticals Virtu Financial Citius Pharmaceuticals Inc Man Group
Source: wkrb13.com

Citius Pharmaceuticals (NASDAQ:CTXR) Rating Reiterated by HC Wainwright

Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 412.82% from the company’s current price. […]
Renaissance Technologies Blair William Co News Ratings For Citius Pharmaceuticals Daily Citius Pharmaceuticals Citius Pharmaceuticals Inc Citius Pharmaceuticals Company Profile

-$0.05 EPS Expected for Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) This Quarter

Wall Street brokerages expect Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) to report earnings per share of ($0.05) for the current quarter, according to Zacks. Zero analysts have made estimates for Citius Pharmaceuticals’ earnings. The highest EPS estimate is ($0.03) and the lowest is ($0.07). Citius Pharmaceuticals also posted earnings of ($0.05) per share in […]
Principal Financial Group Inc Zacks Investment Research Citius Pharmaceuticals Maxim Group Proshare Advisors Citius Pharmaceuticals Inc

Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded to "Hold" at Zacks Investment Research

Zacks Investment Research upgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) from a sell rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports. According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical […]
New Jersey United States Thomson Reuter Allspring Global Investments Holdings Geode Capital Management Zacks Investment Research

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science